Tsfg LLC Buys 45 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Tsfg LLC increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 18.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 288 shares of the medical research company’s stock after purchasing an additional 45 shares during the quarter. Tsfg LLC’s holdings in Charles River Laboratories International were worth $109,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wills Financial Group Inc. lifted its holdings in Charles River Laboratories International by 1.1% in the third quarter. Wills Financial Group Inc. now owns 2,467 shares of the medical research company’s stock valued at $1,018,000 after buying an additional 26 shares during the period. Creative Planning lifted its holdings in Charles River Laboratories International by 1.4% in the third quarter. Creative Planning now owns 2,234 shares of the medical research company’s stock valued at $922,000 after buying an additional 30 shares during the period. Argent Trust Co lifted its holdings in Charles River Laboratories International by 2.4% in the fourth quarter. Argent Trust Co now owns 1,266 shares of the medical research company’s stock valued at $477,000 after buying an additional 30 shares during the period. Intrust Bank NA lifted its holdings in Charles River Laboratories International by 1.1% in the fourth quarter. Intrust Bank NA now owns 3,146 shares of the medical research company’s stock valued at $1,185,000 after buying an additional 33 shares during the period. Finally, Kentucky Retirement Systems lifted its holdings in Charles River Laboratories International by 1.4% in the third quarter. Kentucky Retirement Systems now owns 2,966 shares of the medical research company’s stock valued at $1,224,000 after buying an additional 40 shares during the period. 93.06% of the stock is currently owned by institutional investors and hedge funds.

CRL has been the topic of several analyst reports. KeyCorp cut their price objective on shares of Charles River Laboratories International from $390.00 to $300.00 in a report on Thursday, May 5th. StockNews.com assumed coverage on shares of Charles River Laboratories International in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Stephens assumed coverage on shares of Charles River Laboratories International in a report on Wednesday, April 6th. They issued an “overweight” rating and a $377.00 target price on the stock. UBS Group cut their target price on shares of Charles River Laboratories International from $465.00 to $420.00 and set a “buy” rating on the stock in a report on Thursday, February 17th. Finally, Morgan Stanley cut their target price on shares of Charles River Laboratories International from $465.00 to $430.00 and set an “overweight” rating on the stock in a report on Thursday, February 17th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $387.88.

Charles River Laboratories International stock traded down $2.45 during mid-day trading on Tuesday, reaching $226.40. The company’s stock had a trading volume of 6,609 shares, compared to its average volume of 560,497. The company has a market capitalization of $11.43 billion, a price-to-earnings ratio of 27.87, a price-to-earnings-growth ratio of 1.48 and a beta of 1.27. Charles River Laboratories International, Inc. has a 12 month low of $227.29 and a 12 month high of $460.21. The business’s 50 day simple moving average is $273.52 and its 200 day simple moving average is $326.77. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.04 and a current ratio of 1.34.

Charles River Laboratories International (NYSE:CRLGet Rating) last released its earnings results on Wednesday, May 4th. The medical research company reported $2.75 earnings per share for the quarter, beating analysts’ consensus estimates of $2.72 by $0.03. Charles River Laboratories International had a net margin of 11.64% and a return on equity of 21.90%. The business had revenue of $913.93 million during the quarter, compared to the consensus estimate of $908.64 million. During the same quarter last year, the firm earned $2.53 earnings per share. The firm’s revenue for the quarter was up 10.8% compared to the same quarter last year. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.63 EPS for the current year.

In other news, CEO James C. Foster sold 17,436 shares of Charles River Laboratories International stock in a transaction dated Tuesday, February 22nd. The shares were sold at an average price of $288.67, for a total value of $5,033,250.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph W. Laplume sold 396 shares of Charles River Laboratories International stock in a transaction dated Tuesday, February 22nd. The shares were sold at an average price of $290.83, for a total transaction of $115,168.68. The disclosure for this sale can be found here. In the last three months, insiders sold 38,975 shares of company stock valued at $11,791,146. Insiders own 1.10% of the company’s stock.

Charles River Laboratories International Profile (Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Recommended Stories

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.